Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + ranitidine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves **atorvastatin**, a statin used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, and **ranitidine**, a histamine H2-receptor antagonist that reduces gastric acid secretion. Atorvastatin is primarily used to treat high cholesterol and prevent cardiovascular disease, while ranitidine is used for conditions like ulcers, GERD, and Zollinger-Ellison syndrome.
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on atorvastatin + ranitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + ranitidine.